Ineffective erythropoiesis and regulation of iron status in iron loading anaemias

British Journal of Haematology

Volumn 172, Issue 4, 2016, Pages 512-523

  Camaschella, Clara ^a   Nai, Antonella ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Anaemia; Erythropoiesis; Iron; Iron overload; Thalassaemia

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; ERYTHROFERRONE; ERYTHROPOIETIN; FERROPORTIN; GROWTH DIFFERENTIATION FACTOR 15; HEAT SHOCK PROTEIN 70; HEMOGLOBIN E; HEPCIDIN; JANUS KINASE INHIBITOR; LUSPATERCEPT; REACTIVE OXYGEN METABOLITE; SOTATERCEPT; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TWISTED GASTRULATION PROTEIN HOMOLOG 1; UNCLASSIFIED DRUG; ACTIVIN; ANTIANEMIC AGENT; IRON;

ANEMIA; BETA THALASSEMIA; BLOOD TRANSFUSION; DYSERYTHROPOIESIS; GENE MUTATION; HUMAN; IRON ABSORPTION; IRON CHELATION; IRON DEFICIENCY ANEMIA; IRON LOADING ANEMIA; IRON OVERLOAD; IRON RESTRICTION; IRON STORAGE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDEROBLASTIC ANEMIA; SPLENOMEGALY; THALASSEMIA; THALASSEMIA INTERMEDIA; ANIMAL; BETA-THALASSEMIA; BLOOD; COMPLICATION; DRUG EFFECTS; ERYTHROPOIESIS; METABOLISM; MOUSE; PHYSIOLOGY;

ACTIVINS; ANEMIA; ANIMALS; BETA-THALASSEMIA; ERYTHROPOIESIS; HEMATINICS; HEPCIDINS; HUMANS; IRON; IRON OVERLOAD; MICE;

EID: 84956923279     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13820     Document Type: Review

References (100)

1. Ambaglio, I., Malcovati, L., Papaemmanuil, E., Laarakkers, C.M., Della Porta, M.G., Galli, A., Da Via, M.C., Bono, E., Ubezio, M., Travaglino, E., Albertini, R., Campbell, P.J., Swinkels, D.W. & Cazzola, M. (2013) Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica, 98, 420-423.
2. Andriopoulos, Jr, B., Corradini, E., Xia, Y., Faasse, S.A., Chen, S., Grgurevic, L., Knutson, M.D., Pietrangelo, A., Vukicevic, S., Lin, H.Y. & Babitt, J.L. (2009) BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nature Genetics, 41, 482-487.
3. Angelucci, E., Matthes-Martin, S., Baronciani, D., Bernaudin, F., Bonanomi, S., Cappellini, M.D., Dalle, J.H., Di Bartolomeo, P., de Heredia, C.D., Dickerhoff, R., Giardini, C., Gluckman, E., Hussein, A.A., Kamani, N., Minkov, M., Locatelli, F., Rocha, V., Sedlacek, P., Smiers, F., Thuret, I., Yaniv, I., Cavazzana, M. & Peters, C. (2014) Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica, 99, 811-820.
4. Arlet, J.B., Ribeil, J.A., Guillem, F., Negre, O., Hazoume, A., Marcion, G., Beuzard, Y., Dussiot, M., Moura, I.C., Demarest, S., de Beauchene, I.C., Belaid-Choucair, Z., Sevin, M., Maciel, T.T., Auclair, C., Leboulch, P., Chretien, S., Tchertanov, L., Baudin-Creuza, V., Seigneuric, R., Fontenay, M., Garrido, C., Hermine, O. & Courtois, G. (2014) HSP70 sequestration by free alpha-globin promotes ineffective erythropoiesis in beta-thalassaemia. Nature, 514, 242-246.
5. Bianchi, P., Fermo, E., Vercellati, C., Boschetti, C., Barcellini, W., Iurlo, A., Marcello, A.P., Righetti, P.G. & Zanella, A. (2009) Congenital dyserythropoietic anemia type II (CDAII) is caused by mutations in the SEC23B gene. Human Mutation, 30, 1292-1298.
6. Blank, U. & Karlsson, S. (2011) The role of Smad signaling in hematopoiesis and translational hematology. Leukemia, 25, 1379-1388.
7. Borgna-Pignatti, C., Garani, M.C., Forni, G.L., Cappellini, M.D., Cassinerio, E., Fidone, C., Spadola, V., Maggio, A., Restivo Pantalone, G., Piga, A., Longo, F., Gamberini, M.R., Ricchi, P., Costantini, S., D'Ascola, D., Cianciulli, P., Lai, M.E., Carta, M.P., Ciancio, A., Cavalli, P., Putti, M.C., Barella, S., Amendola, G., Campisi, S., Capra, M., Caruso, V., Colletta, G. & Volpato, S. (2014) Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. British Journal of Haematology, 167, 121-126.
8. Breda, L. & Rivella, S. (2014) Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production. Hematology/Oncology Clinics of North America, 28, 375-386.
9. Bullock, G.C., Delehanty, L.L., Talbot, A.L., Gonias, S.L., Tong, W.H., Rouault, T.A., Dewar, B., Macdonald, J.M., Chruma, J.J. & Goldfarb, A.N. (2010) Iron control of erythroid development by a novel aconitase-associated regulatory pathway. Blood, 116, 97-108.
10. Camaschella, C. (2005) Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood, 106, 3710-3717.
11. Camaschella, C. (2009) Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Seminars in Hematology, 46, 371-377.
12. Camaschella, C. (2013) Treating iron overload. The New England Journal of Medicine, 368, 2325-2327.
13. Carrancio, S., Markovics, J., Wong, P., Leisten, J., Castiglioni, P., Groza, M.C., Raymon, H.K., Heise, C., Daniel, T., Chopra, R. & Sung, V. (2014) An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. British Journal of Haematology, 165, 870-882.
14. Casanovas, G., Swinkels, D.W., Altamura, S., Schwarz, K., Laarakkers, C.M., Gross, H.J., Wiesneth, M., Heimpel, H. & Muckenthaler, M.U. (2011) Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II. Journal of Molecular Medicine, 89, 811-816.
15. Casanovas, G., Vujic Spasic, M., Casu, C., Rivella, S., Strelau, J., Unsicker, K. & Muckenthaler, M.U. (2013) The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica, 98, 444-447.
16. Casu, C., Oikonomidau, R., Shah, Y., Nemeth, E., Ganz, T., MacDonald, B. & Rivella, S. (2014a) Concurrent treatment with minhepcidin and deferiprone improves anemia and enhances reduction of spleen iron in a mouse model of non-transfusion dependent thalassaemia. Blood, 124, 748.
17. Casu, C., Aghajan, M., Oikonomidau, R., Guo, S., Monia, B.P. & Rivella, S. (2014b) Combination of Tmprss6-ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia. Blood, 124, 4024.
18. Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., Cavallesco, R., Gillet-Legrand, B., Caccavelli, L., Sgarra, R., Maouche-Chretien, L., Bernaudin, F., Girot, R., Dorazio, R., Mulder, G.J., Polack, A., Bank, A., Soulier, J., Larghero, J., Kabbara, N., Dalle, B., Gourmel, B., Socie, G., Chretien, S., Cartier, N., Aubourg, P., Fischer, A., Cornetta, K., Galacteros, F., Beuzard, Y., Gluckman, E., Bushman, F., Hacein-Bey-Abina, S. & Leboulch, P. (2010) Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature, 467, 318-322.
19. Cohen, L.A., Gutierrez, L., Weiss, A., Leichtmann-Bardoogo, Y., Zhang, D.L., Crooks, D.R., Sougrat, R., Morgenstern, A., Galy, B., Hentze, M.W., Lazaro, F.J., Rouault, T.A. & Meyron-Holtz, E.G. (2010) Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood, 116, 1574-1584.
20. Corre, J., Hebraud, B. & Bourin, P. (2013) Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Translational Medicine, 2, 946-952.
21. Cuijpers, M.L., Raymakers, R.A., Mackenzie, M.A., de Witte, T.J. & Swinkels, D.W. (2010) Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome. British Journal of Haematology, 149, 322-333.
22. De Falco, L., Silvestri, L., Kannengiesser, C., Moran, E., Oudin, C., Rausa, M., Bruno, M., Aranda, J., Argiles, B., Yenicesu, I., Falcon-Rodriguez, M., Yilmaz-Keskin, E., Kocak, U., Beaumont, C., Camaschella, C., Iolascon, A., Grandchamp, B. & Sanchez, M. (2014) Functional and clinical impact of novel TMPRSS6 variants in iron-refractory iron-deficiency anemia patients and genotype-phenotype studies. Human Mutation, 35, 1321-1329.
23. Du, X., She, E., Gelbart, T., Truksa, J., Lee, P., Xia, Y., Khovananth, K., Mudd, S., Mann, N., Moresco, E.M., Beutler, E. & Beutler, B. (2008) The serine protease TMPRSS6 is required to sense iron deficiency. Science, 320, 1088-1092.
24. Dussiot, M., Maciel, T.T., Fricot, A., Chartier, C., Negre, O., Veiga, J., Grapton, D., Paubelle, E., Payen, E., Beuzard, Y., Leboulch, P., Ribeil, J.A., Arlet, J.B., Cote, F., Courtois, G., Ginzburg, Y.Z., Daniel, T.O., Chopra, R., Sung, V., Hermine, O. & Moura, I.C. (2014) An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia. Nature Medicine, 20, 398-407.
25. Enns, C.A., Ahmed, R., Wang, J., Ueno, A., Worthen, C., Tsukamoto, H. & Zhang, A.S. (2013) Increased iron loading induces Bmp6 expression in the non-parenchymal cells of the liver independent of the BMP-signaling pathway. PLoS ONE, 8, e60534.
26. Fibach, E. & Rachmilewitz, E.A. (2012) Selective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS. Leukemia Research, 36, 962-963.
27. Fields, S.Z., Parshad, S., Anne, M., Raftopoulos, H., Alexander, M.J., Sherman, M.L., Laadem, A., Sung, V. & Terpos, E. (2013) Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opinion on Investigational Drugs, 22, 87-101.
28. Finberg, K.E., Heeney, M.M., Campagna, D.R., Aydinok, Y., Pearson, H.A., Hartman, K.R., Mayo, M.M., Samuel, S.M., Strouse, J.J., Markianos, K., Andrews, N.C. & Fleming, M.D. (2008) Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nature Genetics, 40, 569-571.
29. Finch, C. (1994) Regulators of iron balance in humans. Blood, 84, 1697-1702.
30. Folgueras, A.R., de Lara, F.M., Pendas, A.M., Garabaya, C., Rodriguez, F., Astudillo, A., Bernal, T., Cabanillas, R., Lopez-Otin, C. & Velasco, G. (2008) Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood, 112, 2539-2545.
31. Frisan, E., Vandekerckhove, J., de Thonel, A., Pierre-Eugene, C., Sternberg, A., Arlet, J.B., Floquet, C., Gyan, E., Kosmider, O., Dreyfus, F., Gabet, A.S., Courtois, G., Vyas, P., Ribeil, J.A., Zermati, Y., Lacombe, C., Mayeux, P., Solary, E., Garrido, C., Hermine, O. & Fontenay, M. (2012) Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. Blood, 119, 1532-1542.
32. Gattermann, N., Finelli, C., Della Porta, M., Fenaux, P., Stadler, M., Guerci-Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., Marcellari, A., Roubert, B. & Rose, C. (2012) Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica, 97, 1364-1371.
33. Gelderman, M.P., Baek, J.H., Yalamanoglu, A., Puglia, M., Vallelian, F., Burla, B., Vostal, J., Schaer, D.J. & Buehler, P.W. (2015) Reversal of hemochromatosis by apotransferrin in non-transfused and transfused Hbbth3/+ (heterozygous B1/B2 globin gene deletion) mice. Haematologica, 100, 611-622.
34. Ginzburg, Y. & Rivella, S. (2011) Beta-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood, 118, 4321-4330.
35. Guernsey, D.L., Jiang, H., Campagna, D.R., Evans, S.C., Ferguson, M., Kellogg, M.D., Lachance, M., Matsuoka, M., Nightingale, M., Rideout, A., Saint-Amant, L., Schmidt, P.J., Orr, A., Bottomley, S.S., Fleming, M.D., Ludman, M., Dyack, S., Fernandez, C.V. & Samuels, M.E. (2009) Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nature Genetics, 41, 651-653.
36. Guimaraes, J.S., Cominal, J.G., Silva-Pinto, A.C., Olbina, G., Ginzburg, Y.Z., Nandi, V., Westerman, M., Rivella, S. & de Souza, A.M. (2015) Altered erythropoiesis and iron metabolism in carriers of thalassemia. European Journal of Haematology, 94, 511-518.
37. Guo, S., Casu, C., Gardenghi, S., Booten, S., Aghajan, M., Peralta, R., Watt, A., Freier, S., Monia, B.P. & Rivella, S. (2013) Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. The Journal of Clinical Investigation, 123, 1531-1541.
38. Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T. & Barosi, G. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine, 366, 787-798.
39. Hentze, M.W., Muckenthaler, M.U., Galy, B. & Camaschella, C. (2010) Two to tango: regulation of Mammalian iron metabolism. Cell, 142, 24-38.
40. Hoffbrand, A.V., Taher, A. & Cappellini, M.D. (2012) How I treat transfusional iron overload. Blood, 120, 3657-3669.
41. Iolascon, A., Delaunay, J., Wickramasinghe, S.N., Perrotta, S., Gigante, M. & Camaschella, C. (2001) Natural history of congenital dyserythropoietic anemia type II. Blood, 98, 1258-1260.
42. Iolascon, A., Heimpel, H., Wahlin, A. & Tamary, H. (2013) Congenital dyserythropoietic anemias: molecular insights and diagnostic approach. Blood, 122, 2162-2166.
43. Jensen, P.D., Heickendorff, L., Pedersen, B., Bendix-Hansen, K., Jensen, F.T., Christensen, T., Boesen, A.M. & Ellegaard, J. (1996) The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. British Journal of Haematology, 94, 288-299.
44. Jones, E., Pasricha, S.R., Allen, A., Evans, P., Fisher, C.A., Wray, K., Premawardhena, A., Bandara, D., Perera, A., Webster, C., Sturges, P., Olivieri, N.F., St Pierre, T., Armitage, A.E., Porter, J.B., Weatherall, D.J. & Drakesmith, H. (2015) Hepcidin is suppressed by erythropoiesis in hemoglobin E beta-thalassemia and beta-thalassemia trait. Blood, 125, 873-880.
45. Kautz, L. & Nemeth, E. (2014) Molecular liaisons between erythropoiesis and iron metabolism. Blood, 124, 479-482.
46. Kautz, L., Meynard, D., Monnier, A., Darnaud, V., Bouvet, R., Wang, R.H., Deng, C., Vaulont, S., Mosser, J., Coppin, H. & Roth, M.P. (2008) Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad 7, Id1, and Atoh8 in the mouse liver. Blood, 112, 1503-1509.
47. Kautz, L., Jung, G., Valore, E.V., Rivella, S., Nemeth, E. & Ganz, T. (2014) Identification of erythroferrone as an erythroid regulator of iron metabolism. Nature Genetics, 46, 678-684.
48. Kautz, L., Jung, G., Du, X., Gabayan, V., Chapman, J., Nasoff, M., Nemeth, E. & Ganz, T. (2015) Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia. Blood, doi:blood-2015-07-658419
49. Kerenyi, M.A., Grebien, F., Gehart, H., Schifrer, M., Artaker, M., Kovacic, B., Beug, H., Moriggl, R. & Mullner, E.W. (2008) Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. Blood, 112, 3878-3888.
50. Lakhal-Littleton, S., Wolna, M., Carr, C.A., Miller, J.J., Christian, H.C., Ball, V., Santos, A., Diaz, R., Biggs, D., Stillion, R., Holdship, P., Larner, F., Tyler, D.J., Clarke, K., Davies, B. & Robbins, P.A. (2015) Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function. Proceedings of the National Academy of Sciences of the United States of America, 112, 3164-3169.
51. Levy, J.E., Jin, O., Fujiwara, Y., Kuo, F. & Andrews, N.C. (1999) Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nature Genetics, 21, 396-399.
52. Li, H., Rybicki, A.C., Suzuka, S.M., von Bonsdorff, L., Breuer, W., Hall, C.B., Cabantchik, Z.I., Bouhassira, E.E., Fabry, M.E. & Ginzburg, Y.Z. (2010) Transferrin therapy ameliorates disease in beta-thalassemic mice. Nature Medicine, 16, 177-182.
53. Libani, I.V., Guy, E.C., Melchiori, L., Schiro, R., Ramos, P., Breda, L., Scholzen, T., Chadburn, A., Liu, Y., Kernbach, M., Baron-Luhr, B., Porotto, M., de Sousa, M., Rachmilewitz, E.A., Hood, J.D., Cappellini, M.D., Giardina, P.J., Grady, R.W., Gerdes, J. & Rivella, S. (2008) Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood, 112, 875-885.
54. Lin, L., Valore, E.V., Nemeth, E., Goodnough, J.B., Gabayan, V. & Ganz, T. (2007) Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood, 110, 2182-2189.
55. Malcovati, L., Karimi, M., Papaemmanuil, E., Ambaglio, I., Jadersten, M., Jansson, M., Elena, C., Galli, A., Walldin, G., Della Porta, M.G., Raaschou-Jensen, K., Travaglino, E., Kallenbach, K., Pietra, D., Ljungstrom, V., Conte, S., Boveri, E., Invernizzi, R., Rosenquist, R., Campbell, P.J., Cazzola, M. & Hellstrom Lindberg, E. (2015) SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood, 126, 233-241.
56. Mastrogiannaki, M., Matak, P., Keith, B., Simon, M.C., Vaulont, S. & Peyssonnaux, C. (2009) HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. The Journal of Clinical Investigation, 119, 1159-1166.
57. Meynard, D., Kautz, L., Darnaud, V., Canonne-Hergaux, F., Coppin, H. & Roth, M.P. (2009) Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nature Genetics, 41, 478-481.
58. Musallam, K.M., Sankaran, V.G., Cappellini, M.D., Duca, L., Nathan, D.G. & Taher, A.T. (2012) Fetal hemoglobin levels and morbidity in untransfused patients with beta-thalassemia intermedia. Blood, 119, 364-367.
59. Musallam, K.M., Cappellini, M.D., Daar, S., Karimi, M., El-Beshlawy, A., Graziadei, G., Magestro, M., Wulff, J., Pietri, G. & Taher, A.T. (2014) Serum ferritin level and morbidity risk in transfusion-independent patients with beta-thalassemia intermedia: the ORIENT study. Haematologica, 99, e218-e221.
60. Nai, A., Pagani, A., Mandelli, G., Lidonnici, M.R., Silvestri, L., Ferrari, G. & Camaschella, C. (2012) Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood, 119, 5021-5029.
61. Nai, A., Lidonnici, M.R., Rausa, M., Mandelli, G., Pagani, A., Silvestri, L., Ferrari, G. & Camaschella, C. (2015) The second transferrin receptor regulates red blood cell production in mice. Blood, 125, 1170-1179.
62. Nemeth, E. (2013) Hepcidin and beta-thalassemia major. Blood, 122, 3-4.
63. Origa, R., Galanello, R., Ganz, T., Giagu, N., Maccioni, L., Faa, G. & Nemeth, E. (2007) Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica, 92, 583-588.
64. Pak, M., Lopez, M.A., Gabayan, V., Ganz, T. & Rivera, S. (2006) Suppression of hepcidin during anemia requires erythropoietic activity. Blood, 108, 3730-3735.
65. Papanikolaou, G., Tzilianos, M., Christakis, J.I., Bogdanos, D., Tsimirika, K., MacFarlane, J., Goldberg, Y.P., Sakellaropoulos, N., Ganz, T. & Nemeth, E. (2005) Hepcidin in iron overload disorders. Blood, 105, 4103-4105.
66. Pasricha, S.R., Frazer, D.M., Bowden, D.K. & Anderson, G.J. (2013) Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: a longitudinal study. Blood, 122, 124-133.
67. Piga, A., Perrotta, S., Melpignano, A., Borgna-Pignatti, C., Voskaridou, E., Caruso, V., Filosa, A., Aydinok, Y., Condon, C., Wilson, D.M., Laadem, A., Sherman, M.L. & Attie, K.M. (2014) ACE-536 increases hemoglobin and decreases transfusion burden and serum ferritin in adults with beta-thalassaemia: preliminary results from a phase 2 study. Blood, 124, 53.
68. Platzbecker, U., Germing, U., Giagounidis, A., Goetze, K., Kiewe, P., Mayer, K., Ottman, O., Radsak, M.P., Wolff, T., Haase, D., Hankin, M., Wilson, D.M., Laadem, A., Sherman, M.L. & Attie, K.M. (2014) ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): preliminary results from a phase 2 study. Blood, 124, 411.
69. Preza, G.C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M.A., Sharma, S., Waring, A., Ganz, T. & Nemeth, E. (2011) Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. The Journal of Clinical Investigation, 121, 4880-4888.
70. Ramirez, J.M., Schaad, O., Durual, S., Cossali, D., Docquier, M., Beris, P., Descombes, P. & Matthes, T. (2009) Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. British Journal of Haematology, 144, 251-262.
71. Ramos, E., Ruchala, P., Goodnough, J.B., Kautz, L., Preza, G.C., Nemeth, E. & Ganz, T. (2012) Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood, 120, 3829-3836.
72. Rausa, M., Pagani, A., Nai, A., Campanella, A., Gilberti, M.E., Apostoli, P., Camaschella, C. & Silvestri, L. (2015) Bmp6 expression in murine liver non parenchymal cells: a mechanism to control their high iron exporter activity and protect hepatocytes from iron overload? PLoS ONE, 10, e0122696.
73. Richardson, C.L., Delehanty, L.L., Bullock, G.C., Rival, C.M., Tung, K.S., Kimpel, D.L., Gardenghi, S., Rivella, S. & Goldfarb, A.N. (2013) Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response. The Journal of Clinical Investigation, 123, 3614-3623.
74. Rivella, S. (2015) Beta-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica, 100, 418-430.
75. Santini, V., Girelli, D., Sanna, A., Martinelli, N., Duca, L., Campostrini, N., Cortelezzi, A., Corbella, M., Bosi, A., Reda, G., Olivieri, O. & Cappellini, M.D. (2011) Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS ONE, 6, e23109.
76. Schmidt, P.J., Toudjarska, I., Sendamarai, A.K., Racie, T., Milstein, S., Bettencourt, B.R., Hettinger, J., Bumcrot, D. & Fleming, M.D. (2013) An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood, 121, 1200-1208.
77. Schmidt, P.J., Racie, T., Westerman, M., Fitzgerald, K., Butler, J.S. & Fleming, M.D. (2015) Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of beta-thalassemia intermedia. American Journal of Hematology, 90, 310-313.
78. Schwarz, K., Iolascon, A., Verissimo, F., Trede, N.S., Horsley, W., Chen, W., Paw, B.H., Hopfner, K.P., Holzmann, K., Russo, R., Esposito, M.R., Spano, D., De Falco, L., Heinrich, K., Joggerst, B., Rojewski, M.T., Perrotta, S., Denecke, J., Pannicke, U., Delaunay, J., Pepperkok, R. & Heimpel, H. (2009) Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II. Nature Genetics, 41, 936-940.
79. Seldin, M.M., Peterson, J.M., Byerly, M.S., Wei, Z. & Wong, G.W. (2012) Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. The Journal of Biological Chemistry, 287, 11968-11980.
80. Seldin, M.M., Lei, X., Tan, S.Y., Stanson, K.P., Wei, Z. & Wong, G.W. (2013) Skeletal muscle-derived myonectin activates the mammalian target of rapamycin (mTOR) pathway to suppress autophagy in liver. The Journal of Biological Chemistry, 288, 36073-36082.
81. Shah, Y.M., Matsubara, T., Ito, S., Yim, S.H. & Gonzalez, F.J. (2009) Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metabolism, 9, 152-164.
82. Shalev, H., Perez-Avraham, G., Kapelushnik, J., Levi, I., Rabinovich, A., Swinkels, D.W., Brasse-Lagnel, C. & Tamary, H. (2013) High levels of soluble serum hemojuvelin in patients with congenital dyserythropoietic anemia type I. European Journal of Haematology, 90, 31-36.
83. Shenoy, N., Vallumsetla, N., Rachmilewitz, E., Verma, A. & Ginzburg, Y. (2014) Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood, 124, 873-881.
84. Sherman, M.L., Borgstein, N.G., Mook, L., Wilson, D., Yang, Y., Chen, N., Kumar, R., Kim, K. & Laadem, A. (2013) Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. Journal of Clinical Pharmacology, 53, 1121-1130.
85. Silvestri, L., Pagani, A. & Camaschella, C. (2008) Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood, 111, 924-931.
86. Sonnweber, T., Nachbaur, D., Schroll, A., Nairz, M., Seifert, M., Demetz, E., Haschka, D., Mitterstiller, A.M., Kleinsasser, A., Burtscher, M., Trubsbach, S., Murphy, A.T., Wroblewski, V., Witcher, D.R., Mleczko-Sanecka, K., Vecchi, C., Muckenthaler, M.U., Pietrangelo, A., Theurl, I. & Weiss, G. (2014) Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut, 63, 1951-1959.
87. Suragani, R.N., Cadena, S.M., Cawley, S.M., Sako, D., Mitchell, D., Li, R., Davies, M.V., Alexander, M.J., Devine, M., Loveday, K.S., Underwood, K.W., Grinberg, A.V., Quisel, J.D., Chopra, R., Pearsall, R.S., Seehra, J. & Kumar, R. (2014a) Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nature Medicine, 20, 408-414.
88. Suragani, R.N., Cawley, S.M., Li, R., Wallner, S., Alexander, M.J., Mulivor, A.W., Gardenghi, S., Rivella, S., Grinberg, A.V., Pearsall, R.S. & Kumar, R. (2014b) Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine beta-thalassemia. Blood, 123, 3864-3872.
89. Taher, A.T., Musallam, K.M., Karimi, M., El-Beshlawy, A., Belhoul, K., Daar, S., Saned, M.S., El-Chafic, A.H., Fasulo, M.R. & Cappellini, M.D. (2010) Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood, 115, 1886-1892.
90. Taher, A.T., Musallam, K.M., Cappellini, M.D. & Weatherall, D.J. (2011) Optimal management of beta thalassaemia intermedia. British Journal of Haematology, 152, 512-523.
91. Taher, A., Vichinsky, E., Musallam, K., Cappellini, M.D. & Viprakasit, V. (2013) Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT) (ed. by D. Weatherall ). Thalassaemia International Federation, Nicosia, Cyprus.
92. Tamary, H., Shalev, H., Perez-Avraham, G., Zoldan, M., Levi, I., Swinkels, D.W., Tanno, T. & Miller, J.L. (2008) Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood, 112, 5241-5244.
93. Tanno, T., Porayette, P., Sripichai, O., Noh, S.J., Byrnes, C., Bhupatiraju, A., Lee, Y.T., Goodnough, J.B., Harandi, O., Ganz, T., Paulson, R.F. & Miller, J.L. (2009) Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood, 114, 181-186.
94. Tanno, T., Noel, P. & Miller, J.L. (2010) Growth differentiation factor 15 in erythroid health and disease. Current Opinion in Hematology, 17, 184-190.
95. Taoka, K., Kumano, K., Nakamura, F., Hosoi, M., Goyama, S., Imai, Y., Hangaishi, A. & Kurokawa, M. (2012) The effect of iron overload and chelation on erythroid differentiation. International Journal of Hematology, 95, 149-159.
96. Weatherall, D.J. (2012) The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Reviews, 26, S3-S6.
97. Zhao, W., Kitidis, C., Fleming, M.D., Lodish, H.F. & Ghaffari, S. (2006) Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood, 107, 907-915.
98. Zhao, N., Nizzi, C.P., Anderson, S.A., Wang, J., Ueno, A., Tsukamoto, H., Eisenstein, R.S., Enns, C.A. & Zhang, A.S. (2015) Low intracellular iron increases the stability of matriptase-2. The Journal of Biological Chemistry, 290, 4432-4446.
99. Zhou, L., Nguyen, A.N., Sohal, D., Ying Ma, J., Pahanish, P., Gundabolu, K., Hayman, J., Chubak, A., Mo, Y., Bhagat, T.D., Das, B., Kapoun, A.M., Navas, T.A., Parmar, S., Kambhampati, S., Pellagatti, A., Braunchweig, I., Zhang, Y., Wickrema, A., Medicherla, S., Boultwood, J., Platanias, L.C., Higgins, L.S., List, A.F., Bitzer, M. & Verma, A. (2008) Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood, 112, 3434-3443.
100. Zipperer, E., Post, J.G., Herkert, M., Kundgen, A., Fox, F., Haas, R., Gattermann, N. & Germing, U. (2013) Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome. Annals of Hematology, 92, 1617-1623.